Mutated ATM and unmutated IGHV were identified as potential early drivers of disease in treatment-naive patients with chronic lymphocytic leukemia.
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy.
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Results of this study suggest that the clonal and subclonal characteristics of early-stage CLL shape the dynamics of the disease course.
Patients with CLL who had symptomatic bronchial involvement had a significantly higher proportion of anomalies in small airways and peripheral bronchi.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Interestingly, over two-thirds of patients did not receive active treatment for CLL during the study period.
Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.
Chimeric antigen receptor T-cell therapy “liso-cel” was deemed safe and clinically active in chronic lymphocytic leukemia and small lymphocytic leukemia.
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
A phase 3 study of single-agent acalabrutinib versus rituximab plus idelasib or bendamustine in RR/CLL will be closed early due to favorable results at interim analysis.
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
An integrated assessment of the results from 2 assays showed promise for tailoring ibrutinib-based targeted therapy in patients with CLL.
At a follow-up of almost 4 years, over two-thirds of patients randomly assigned to receive ofatumumab crossed over to receive ibrutinib.
Relative increases in health care costs associated with disease progression were more than 30% in subgroups of patients with CLL and NHL.
Sequential multiple assignment randomized trials (SMART) have an adaptive design based on patient response to therapy.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it’s a mutation that may be detected years before clinical relapse occurs.